Catalyst Pharmaceuticals, Inc. [CPRX] saw a change by 4.90% with the Thursday trading session, closing the trade at the price of $3.85. The company is holding 101.34M shares with keeping 95.77M floating shares. With the latest trading session, the stock is set at 108.11% off compared to its 52-week low, sliding -37.50% from high for the same period of time.
Since its 90-day high, the share price saw a move by -37.50%, trading +72.49% in oppose to its 90-day low While during the day, 101.34M shares valued at 2.08 million were bought and sold.
Catalyst Pharmaceuticals, Inc. [NASDAQ:CPRX]: Analyst Rating and Earnings
Pro stock market traders often keep their attention pointed at what top market analysts have to say regarding a potential equity investment. For Catalyst Pharmaceuticals, Inc. [CPRX] currently, the latest-available mean analyst rating is for the fiscal quarter that will end in December. On average, stock market experts give CPRX an Outperform rating. Its stock price has been found in the range of 1.85 to 6.16. This is compared to its latest closing price of $3.67.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Catalyst Pharmaceuticals, Inc. [CPRX] is sitting at 1.83. This is compared to 1 month ago, when its average rating was 1.83.
Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Tue 6 Aug (In 53 Days).
Fundamental Analysis of Catalyst Pharmaceuticals, Inc. [CPRX]
Now let’s turn to look at profitability: with a current Operating Margin for Catalyst Pharmaceuticals, Inc. [CPRX] sitting at -7059.03.
This company’s Return on Total Capital is -53.58, and its Return on Invested Capital has reached -69.50%. Its Return on Equity is -51.62, and its Return on Assets is -46.63. These metrics suggest that this Catalyst Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -8.49. The Enterprise Value to Sales for this firm is now 23.12. Catalyst Pharmaceuticals, Inc. [CPRX] has a Price to Book Ratio of 3.88.
Shifting the focus to workforce efficiency, Catalyst Pharmaceuticals, Inc. [CPRX] earns $9,804 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 5.80 and its Current Ratio is 5.80. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Catalyst Pharmaceuticals, Inc. [CPRX] has 101.34M shares outstanding, amounting to a total market cap of $390.16M. Its stock price has been found in the range of 1.85 to 6.16. At its current price, it has moved down by -37.50% from its 52-week high, and it has moved up 108.11% from its 52-week low.
This stock’s Beta value is currently 2.64, which indicates that it is 8.70% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 51.47. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Catalyst Pharmaceuticals, Inc. [CPRX] a Reliable Buy?
Shares of Catalyst Pharmaceuticals, Inc. [CPRX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.